SlateStone Wealth LLC Decreases Position in TransMedics Group, Inc. (NASDAQ:TMDX)

SlateStone Wealth LLC cut its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 61.3% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 3,271 shares of the company’s stock after selling 5,187 shares during the period. SlateStone Wealth LLC’s holdings in TransMedics Group were worth $204,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the company. Geode Capital Management LLC grew its stake in shares of TransMedics Group by 1.3% in the third quarter. Geode Capital Management LLC now owns 763,790 shares of the company’s stock worth $119,938,000 after acquiring an additional 10,106 shares during the period. Vaughan Nelson Investment Management L.P. grew its stake in shares of TransMedics Group by 9.9% in the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 361,615 shares of the company’s stock worth $22,547,000 after acquiring an additional 32,605 shares during the period. Charles Schwab Investment Management Inc. grew its stake in shares of TransMedics Group by 9.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 297,433 shares of the company’s stock worth $18,545,000 after acquiring an additional 25,739 shares during the period. Baillie Gifford & Co. grew its stake in shares of TransMedics Group by 14.9% in the fourth quarter. Baillie Gifford & Co. now owns 269,836 shares of the company’s stock worth $16,824,000 after acquiring an additional 34,947 shares during the period. Finally, Principal Financial Group Inc. grew its stake in shares of TransMedics Group by 260.1% in the third quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock worth $31,759,000 after acquiring an additional 146,115 shares during the period. 99.67% of the stock is owned by hedge funds and other institutional investors.

TransMedics Group Stock Down 1.2 %

Shares of TMDX stock opened at $67.69 on Tuesday. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $177.37. The stock has a market cap of $2.28 billion, a P/E ratio of 72.01 and a beta of 2.12. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The company has a 50 day simple moving average of $68.43 and a two-hundred day simple moving average of $92.75.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on TMDX. Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a research note on Wednesday, February 5th. Oppenheimer reiterated an “outperform” rating and issued a $125.00 price target on shares of TransMedics Group in a research note on Tuesday, December 3rd. Robert W. Baird reduced their price target on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a research note on Wednesday, December 11th. Piper Sandler cut their target price on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a research report on Wednesday, December 11th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $75.00 target price (down from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $122.70.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.